Xilio Therapeutics (XLO) EPS (Basic) (2020 - 2026)
Xilio Therapeutics' (XLO) quarterly EPS (Basic) came in at -$0.18 in Q2 2026, up 91.37% year-over-year from -$0.09 in Q2 2025, and up 79.16% quarter-over-quarter from -$0.86 in Q1 2026.
Powered by 
Analysis
Xilio Therapeutics (XLO) EPS (Basic) (2020 - 2026) Analysis & Trends
Xilio Therapeutics has disclosed EPS (Basic) across 7 years of filings, most recently posting -$0.18 for Q2 2026.
- In Q2 2026, EPS (Basic) rose 91.37% year-over-year to -$0.18; the TTM figure through Jun 2026 stood at -$1.62 (up 80.33% YoY), while the FY2025 annual figure was -$5.02, up 68.31% from the prior year.
- EPS (Basic) came in at -$0.18 for Q2 2026 at Xilio Therapeutics, up from -$0.86 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$0.18 in Q2 2026 to a low of -$12.55 in Q2 2022.
- Average EPS (Basic) over 5 years is -$6.25, with a median of -$6.17 recorded in 2024.
- Year-over-year, EPS (Basic) surged 97.13% in 2022 and retreated 9.91% in 2023.
- Over 5 years, EPS (Basic) stood at -$11.84 in 2022, then climbed by 22.04% to -$9.23 in 2023, then jumped by 61.37% to -$3.57 in 2024, then soared by 60.29% to -$1.42 in 2025, then jumped by 87.29% to -$0.18 in 2026.
- Per Business Quant data, the three most recent EPS (Basic) figures were -$0.18 in Q2 2026, -$0.86 in Q1 2026, and -$1.42 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -0.40 |
| 10 | Xilio Therapeutics | 174.55 Mn | 38.51 Mn | - | -0.18 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.18 |
| Mar 31, 2026 | -0.86 |
| Dec 31, 2025 | -1.42 |
| Sep 30, 2025 | -0.19 |
| Jun 30, 2025 | -2.09 |
| Mar 31, 2025 | -2.60 |
| Dec 31, 2024 | -3.57 |
| Sep 30, 2024 | -3.26 |
| Jun 30, 2024 | -3.56 |
| Mar 31, 2024 | -8.77 |
| Dec 31, 2023 | -9.23 |
| Sep 30, 2023 | -8.83 |
| Jun 30, 2023 | -10.25 |
| Mar 31, 2023 | -12.01 |
| Dec 31, 2022 | -11.84 |
| Sep 30, 2022 | -10.32 |
| Jun 30, 2022 | -12.55 |
| Mar 31, 2022 | -10.92 |
| Dec 31, 2021 | -49.27 |
| Sep 30, 2021 | -297.84 |